CTAP: There is nothing on the FDA website that add

CTAP: There is nothing on the FDA website that addresses the Leronlimab CD12 interim analysis.

The CTAP info on the FDA website days abslutely nothing that differentiates CTAP from the other FDA administrative protocols.

The only difference I can see is that the FDA is paying more attention to stuff in CTAP.

But other than that, there is no protocol distinction between CTAP and all the rest of the FDA protocols.

In particular, there is no discussion whatsoever of interim analyses or FDA unblinding to the results on interim analyses.

There is no discussion whatsoever or evan any hint of the FDA participating in the data analysis for an interim analysis, which is the case in CD12 if Seethamraju is correct.

There are references to at least hundreds of clinical trials which are inside of CTAP protocol.

My question is: Does there exist any FDA unblinding of an interim analysis other than CYDY CD12?

Google Search on "fda unblinding" "interim analysis" should be able to answer that question.

Besides ads, there are two hits.

Cick on the first and you get the laugh out loud message "403. That's an error. We're sorry but you do not have access to this page. That's all we kow."

The second hit looks like a malware download but I don't know maybe not. I was not brave enough to try it